The final GLOW analysis reports durable progression-free and overall-survival advantages for fixed-duration ibrutinib plus venetoclax over chlorambucil plus obinutuzumab in older or comorbid untreated chronic lymphocytic leukemia. The long follow-up strengthens the regimen’s internal…
A peer-reviewed Phase 1b/2 study of zilovertamab plus ibrutinib shows ROR1 occupancy and pathway modulation, but the small randomized cohort did not improve complete response, overall response or progression-free survival versus ibrutinib alone. An…
Foghorn and Lilly will not advance the Phase 1 SMARCA2 inhibitor FHD-909 into expansion and will also stop their selective SMARCA2 degrader program. Foghorn disclosed an approximately 40% workforce reduction and said it will…
FDA expanded CAMZYOS to symptomatic obstructive hypertrophic cardiomyopathy in adults and pediatric patients weighing at least 30 kilograms, making mavacamten the first approved therapy specifically for pediatric obstructive HCM. In the randomized Phase 3…
Sarepta reported new ELEVIDYS analyses at the World Muscle Society meeting. Twenty-five patients dosed at ages eight to 12 showed a 3.32-point North Star Ambulatory Assessment advantage at two years versus 99 matched natural-history…
Pierre Fabre, supported by Atara Biotherapeutics, resubmitted the U.S. biologics license application for tabelecleucel in adults and children at least two years old with relapsed or refractory Epstein-Barr virus-positive post-transplant lymphoproliferative disease after at…
